Mounjaro
Tirzepatide · Once a week
€300 per month
Mounjaro contains tirzepatide and is authorised in Europe for weight management in adults who meet the medical criteria. It is administered by injection once a week and acts on both GIP and GLP-1 receptors.
* In studies, the average weight loss varied depending on the dose used. Results vary from person to person and are not guaranteed.
That’s why you choose WeightConsult
What is Mounjaro?
Tirzepatide works via two hormonal signalling pathways
Mounjaro contains tirzepatide. This active substance activates both GIP and GLP-1 receptors: hormonal systems involved in, amongst other things, appetite, food intake and metabolism.
Mounjaro is authorised in Europe for weight management in adults who are obese, or who are overweight and have at least one weight-related condition, in combination with a modified diet and increased physical activity.
Loss of appetite
Tirzepatide affects the signals involved in hunger and food intake.
Greater satiety
A greater sense of fullness can help you eat less on a regular basis.
Dual action
Tirzepatide acts via both GIP and GLP-1 receptors, thereby distinguishing itself from semaglutide and liraglutide.
Use and structure
Mounjaro is taken once a week
The usual starting dose is 2.5 mg once a week. After four weeks, this is increased to 5 mg. If a further increase is deemed appropriate, this is done in increments of 2.5 mg, and only after the patient has been on the current dose for at least four weeks.
This is the standard dosage regimen as set out in the product information and does not constitute personalised dosage advice. The doctor will determine the appropriate dosage.
Result
What did the research on tirzepatide show?
In a large study of adults who were obese or overweight but did not have diabetes, a clear dose-dependent reduction in body weight was observed. On average, body weight decreased by 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg.
* Research findings do not guarantee individual results. Results depend, amongst other things, on dosage, lifestyle, duration of treatment and personal circumstances.
Side effects and safety
What are the common side effects?
The most common side effects of Mounjaro are gastrointestinal symptoms. These occur more frequently when the dose is increased and are usually mild to moderate.
Common complaints
The official product information lists nausea and diarrhoea, amongst other things, as very common side effects. Constipation and vomiting may also occur.
That is why we carry out an assessment in advance
Mounjaro is available on prescription only and is not suitable for everyone. Your doctor will assess your medical history, current medication, any potential contraindications and whether treatment is appropriate in your case.
How WeightConsult works
From the initial check-up to ongoing support
You don’t need to decide in advance which treatment is best for you. The doctor will assess which options are medically appropriate and discuss this with you.
BMI check
Initial indication.
Medical assessment
Health and medication.
Doctor’s appointment + consultation
Assessment and treatment plan.
Getting started + support
The chemist’s and what happened next.
Cost
How much does treatment with Mounjaro cost?
The costs depend on the dosage and the stage of treatment. As Mounjaro can be titrated gradually, we keep the current price list updated centrally on our fees page.
Find out the current price per treatment phase and what is included in the programme.
View Mounjaro rates →Frequently asked questions
Short answers to questions about Mounjaro
Yes. Mounjaro is authorised in Europe for weight management in adults who are obese, or who are overweight and have at least one weight-related condition, in addition to a modified diet and increased physical activity.
In a large study of people without diabetes, the average weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg. Individual results may vary.
Mounjaro is injected under the skin once a week.
The usual starting dose is 2.5 mg per week. After four weeks, this is increased to 5 mg. If a further increase is necessary and appropriate, this can be done in increments of 2.5 mg up to a maximum of 15 mg per week.
Mounjaro contains tirzepatide and acts via both GIP and GLP-1 receptors. Wegovy contains semaglutide and acts via the GLP-1 receptor. A doctor will assess which treatment is appropriate.
Gastrointestinal symptoms are particularly common, including nausea, diarrhoea, constipation and vomiting. These symptoms are more frequently observed during dose escalation.
Yes. Mounjaro is available on prescription only. A doctor will determine whether treatment is medically appropriate in your case.
Ready to take the next step?
Check whether a treatment is right for you
You now know how the fees are structured and what treatment options are available. So the next step is simple: start with the BMI check and find out whether you might be able to proceed to the medical assessment.
A positive BMI check does not constitute medical approval.